首页> 外文期刊>Autoimmunity >Development of novel therapies for MG: Studies in animal models
【24h】

Development of novel therapies for MG: Studies in animal models

机译:MG新疗法的开发:动物模型研究

获取原文
获取原文并翻译 | 示例
           

摘要

Experimental myasthenia gravis (MG) in animals, and in particular experimental autoimmune MG in rodents, serves as excellent models to study possible novel therapeutic modalities for MG. The current treatments for MG are based on cholinesterase inhibitors, general immunosuppressants, and corticosteroids, broad immunomodulatory therapies such as plasma exchange or intravenous immunoglobulins (IVIGs), and thymectomy for selected patients. This stresses the need for immunotherapies that would specifically or preferentially suppress the undesirable autoimmune response without widely affecting the entire immune system as most available treatments do. The available animal models for MG enable to perform preclinical studies in which novel therapeutic approaches can be tested. In this review, we describe the different therapeutic approaches that were so far tested in experimental models of MG and discuss their underlying mechanisms of action. These include antigen - acetylcholine receptor (AChR)-dependent treatments aimed at specifically abrogating the humoral and cellular anti-AChR responses as well as immunomodulatory approaches that could be used either alone or in conjunction with antigen-specific treatments or alternatively serve as steroid sparing agents. The antigen-specific treatments are based on fragments or peptides derived from the acetylcholine receptor (AChR) that would theoretically deviate the anti-AChR autoimmune response away from the muscle target or on ways to target AChR-specific T- and B- cell responses or antibodies. The immunomodulatory modalities include cell-based and non-cell-based ways to affect or manipulate key players in the autoimmune process such as regulatory T cells, dendritic cells, cytokine networks, and chemokine and costimulatory signaling as well as complement pathways. We also describe approaches that attempt to affect the cholinergic balance, which is impaired at the neuromuscular junction. In addition to enabling to test the feasib
机译:动物中的实验性重症肌无力(MG),尤其是啮齿动物中的实验性自身免疫性MG,是研究MG可能的新型治疗方式的出色模型。 MG的当前治疗方法基于胆碱酯酶抑制剂,一般免疫抑制剂和皮质类固醇,广泛的免疫调节疗法(例如血浆置换或静脉内免疫球蛋白(IVIG))以及针对特定患者的胸腺切除术。这强调了对免疫疗法的需要,该疗法可以特异性或优先抑制不需要的自身免疫反应,而不会像大多数现有治疗方法那样广泛影响整个免疫系统。 MG的可用动物模型能够进行临床前研究,在其中可以测试新颖的治疗方法。在这篇综述中,我们描述了迄今为止在MG实验模型中测试过的各种治疗方法,并讨论了它们的潜在作用机制。这些措施包括旨在特异性消除体液和细胞抗AChR反应的抗原-乙酰胆碱受体(AChR)依赖性治疗,以及可以单独使用或与抗原特异性治疗结合使用或作为类固醇保护剂使用的免疫调节方法。 。抗原特异性治疗基于衍生自乙酰胆碱受体(AChR)的片段或肽,这些片段或肽在理论上会使抗AChR自身免疫反应偏离肌肉靶标,或靶向AChR特异性T细胞和B细胞反应或抗体。免疫调节方式包括影响或操纵自身免疫过程中关键参与者的基于细胞和基于非细胞的方式,例如调节性T细胞,树突状细胞,细胞因子网络,趋化因子和共刺激信号传导以及补体途径。我们还描述了试图影响胆碱能平衡的方法,胆碱能平衡在神经肌肉接头处受损。除了能够测试可行性

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号